Tonix Pharmaceuticals (NASDAQ:TNXP) Coverage Initiated at StockNews.com

Analysts at StockNews.com started coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a report issued on Tuesday. The firm set a “sell” rating on the stock.

Separately, Dawson James started coverage on shares of Tonix Pharmaceuticals in a research note on Wednesday, February 28th. They issued a “buy” rating and a $3.00 price objective for the company.

Tonix Pharmaceuticals Trading Down 2.4 %

Tonix Pharmaceuticals stock opened at $0.33 on Tuesday. Tonix Pharmaceuticals has a 1-year low of $0.26 and a 1-year high of $4.00. The firm has a market capitalization of $8.75 million, a price-to-earnings ratio of -0.03 and a beta of 2.28. The firm has a 50 day simple moving average of $0.34 and a 200 day simple moving average of $0.46.

Institutional Trading of Tonix Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the stock. Renaissance Technologies LLC lifted its stake in Tonix Pharmaceuticals by 1.2% in the first quarter. Renaissance Technologies LLC now owns 1,222,424 shares of the company’s stock worth $723,000 after purchasing an additional 14,200 shares during the last quarter. Geode Capital Management LLC lifted its stake in Tonix Pharmaceuticals by 8.1% in the fourth quarter. Geode Capital Management LLC now owns 371,852 shares of the company’s stock worth $144,000 after purchasing an additional 27,892 shares during the last quarter. Two Sigma Investments LP lifted its stake in Tonix Pharmaceuticals by 183.9% in the first quarter. Two Sigma Investments LP now owns 60,191 shares of the company’s stock worth $36,000 after purchasing an additional 38,991 shares during the last quarter. Virtu Financial LLC lifted its stake in Tonix Pharmaceuticals by 44.8% in the fourth quarter. Virtu Financial LLC now owns 188,075 shares of the company’s stock worth $73,000 after purchasing an additional 58,184 shares during the last quarter. Finally, UBS Group AG lifted its stake in Tonix Pharmaceuticals by 18,868.5% in the fourth quarter. UBS Group AG now owns 67,528 shares of the company’s stock worth $26,000 after purchasing an additional 67,172 shares during the last quarter. 82.26% of the stock is owned by institutional investors.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.